AlphAIalphai — Financial news for AI agents
benzinga.comJUL 204 min read$STIM

Why Is Neuronetics Stock Soaring Monday? - Neuronetics (NASDAQ:STIM)

Neuronetics (STIM) shares rose more than 28% Monday after BTIG initiated coverage with a Buy rating and a $5 price forecast, based on 2.5 times estimated sales. The article links the move to Neuronetics’ 2024 Greenbrook TMS acquisition, adding TMS and Spravato. It cites Q1 results: loss of 16 cents and sales of $34.454M.

Original reporting
benzinga.com
Published Jul 20, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Is Neuronetics Stock Soaring Monday? - Neuronetics (NASDAQ:STIM) — source image
Source · benzinga.com
Decision brief

The 30-second read

$STIMBullishMed
01

Why it matters

The article attributes Monday’s surge to analyst initiation (Buy, $5 PT) and cites supportive Q1 financials and platform expansion, while reiterating reimbursement and execution risks.

02

Market read

A same-day, company-specific catalyst (analyst initiation with a quantified PT) plus cited Q1 results explains the magnitude of the move and frames near-term trading sentiment.

03

What to watch

Sustaining gains likely hinges on SPRAVATO program expansion economics and payer reimbursement outcomes, which the article flags as risks but does not quantify.

Relevance 7/10Novelty 6/10Timing: Monday’s session, immediately after the analyst initiation and the reported 28.40% surge.

Background

Neuronetics is positioned as a mental health platform after its 2024 Greenbrook TMS acquisition, adding TMS and SPRAVATO alongside its NeuroStar system.

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics shares jumped 28% after analyst initiation, with Q1 sales and loss numbers plus a $5 PT tied to its TMS and psychedelic-therapy positioning.

Expected impact

Near-term upside bias likely persists while momentum and the $5 PT narrative circulate, but follow-through depends on execution and reimbursement risk.

Evidence & confidence

The article’s actionable driver is the new analyst initiation (Buy, $5 forecast) alongside reported Q1 results and acquisition-driven platform expansion; no new clinical/regulatory datapoint is disclosed beyond these reported figures.

Market effects

Sector

Reinforces investor interest in TMS and esketamine-adjacent mental health platforms, potentially supporting sentiment for other interventional mental health device and therapy plays.

Regional

Primarily US small/mid-cap biotech/medtech sentiment via NASDAQ trading and analyst coverage.

Global

Limited global read-through; the story is company-specific with a US-listed issuer and FDA-cleared therapy references.

Counterpoint

What could challenge this read

The rally may be more about analyst framing and momentum than new fundamental catalysts, given the article highlights execution and reimbursement risks without new trial or regulatory milestones.

Key entities

  • company
    Neuronetics

    NASDAQ-listed mental health platform company whose shares surged after analyst initiation and Q1 results were cited.

  • acquisition
    Greenbrook TMS

    2024 acquisition that added TMS and SPRAVATO to Neuronetics’ platform.

  • analyst_firm
    BTIG

    Initiated coverage with a Buy rating and a $5 price forecast based on a forward sales multiple.

  • partnership
    ANT Neuro

    Partnership mentioned to expand NeuroStar Advanced Therapy System with image-guided navigation.

Read at source← All news

Related articles

AUG 18
$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

fool.com6 min
AUG 13
Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

yahoo.com5 min
AUG 13
$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

yahoo.com6 min
AUG 11
$STIMHighAI 8/10

Why is Neuronetics stock surging today?

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

investing.com3 min
AUG 11
$STIMMed

Neuronetics, Inc. (STIM): Results of Operations and Financial Condition

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar ® TMS technology with direc

SEC EDGAR 8-K6 min